Barclays Rates RXO buy, $28 Price Target
Barclays maintains its buy rating on RXO, setting a price target of $28, a 4.09% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated RXO, Inc. ($RXO) "buy" with a $28 price target on June 26, 2026.
Since the rating, $RXO is down 1.9% after 1 week, down 11.1% after 1 month and up 5.5% to date (from the $27.12 close on Jun 26, 2026).
RXO
RXO, Inc.
Key Points
- Barclays analyst Brandon Oglenski reiterated a buy rating on RXO with a $28 price target on June 26, 2026.
- Barclays's $28 price target implies 4.09% upside from RXO, Inc.'s ($RXO) current $26.90 share price.
- Shares of RXO traded at $26.9 on Saturday, reflecting ongoing interest from institutional investors.
- Insider activity includes significant trades by CEO Andrew Wilkerson, while Orbis Allan Gray and others adjusted their RXO holdings.
Get $RXO trade alerts by text
We text you when insiders, Congress or big funds trade $RXO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated RXO, Inc. alert may contain errors. Disclosures
Barclays analyst Brandon Oglenski reiterated a buy rating on RXO on June 26, 2026, setting a price target of $28. This reaffirmation underscores the firm's positive outlook for the company.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in RXO
Several institutional investors have recently adjusted their positions in RXO. Orbis Allan Gray Ltd increased its holdings by 1,720,219 shares, bringing its total to about 36.4 million shares valued at approximately $532.1 million, marking a 5.0% increase. MFN Partners Management, LP also added 532,276 shares, now holding about 28.1 million shares worth $410.9 million, a 1.9% rise. BlackRock, Inc. grew its stake by 267,801 shares to a total of around 24.2 million shares valued at $353.3 million, reflecting a 1.1% increase. Finepoint Capital LP boosted its position by 684,829 shares, ending with about 10.1 million shares valued at $147.3 million, a 7.3% increase. Both Vanguard Portfolio Management LLC and Vanguard Capital Management LLC opened new positions, with holdings of approximately 9.0 million and 7.4 million shares, respectively.
RXO, Inc. Stock Up 32.8%
Shares of RXO traded near $26.9 on Saturday. The stock has been showing interest from both analysts and institutional investors, with a range of price targets reflecting varying levels of optimism.
$RXO price target
RXO, Inc. daily closes and this analyst's $28 target. Not advice.
Insider Buying and Selling at RXO, Inc.
Recent insider activity at RXO includes several transactions by CEO Andrew Wilkerson and Chief Accounting Officer Daniel Morris. On May 15, 2026, Wilkerson both bought and sold 168,943 shares, while Morris acquired 13,377 shares. Earlier, on May 2, 2026, Wilkerson made several trades, including selling 40,370 shares at an average price of $19.59.
Analysts Set New Price Targets
On June 26, 2026, Barclays maintained its buy rating on RXO with a price target of $28. Earlier, on May 15, 2026, Stifel upgraded the stock to a buy with a $22 target. Other firms like UBS and Citigroup maintained hold ratings with targets of $22 and $24, respectively. The consensus among analysts suggests a range of opinions, with a general buy recommendation prevailing.
Bottom Line
Barclays' reiteration of a buy rating for RXO, along with a $28 price target, reflects confidence in the company's prospects. Institutional interest and insider transactions indicate active engagement with RXO's stock. As always, investors should consider these insights as part of a broader investment strategy, remembering that analyst ratings reflect opinions at a specific point in time.
Related Filing Alerts
Source: Barclays's rating change on $RXO (Jun 26, 2026). Written by software, not financial advice. How we make alerts